MENU
+Compare
CNCR
ETF ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$12.35
Change
+$0.03 (+0.24%)
Net Assets
10.24M

CNCR stock forecast, quote, news & analysis

Category: @Health
CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CNCR with price predictions
Dec 24, 2024

CNCR's Stochastic Oscillator is remaining in oversold zone for 9 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CNCR's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNCR advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

CNCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CNCR as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CNCR turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CNCR entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index. The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

Market Cap

The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.8B. The market cap for tickers in the group ranges from 12.4M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is APLM at 12.4M.

High and low price notable news

The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was -2%. For the same ETF, the average monthly price growth was -9%, and the average quarterly price growth was -9%. RAPT experienced the highest price growth at 106%, while MRSN experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was -49%. For the same stocks of the ETF, the average monthly volume growth was -45% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 83
Price Growth Rating: 67
SMR Rating: 92
Profit Risk Rating: 91
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ETF Series Solutions615 East Michigan Street, Milwaukee, WisconsinEast Michigan
Phone
(414) 765-5586
Web
N/A